A Next-generation genetically attenuated plasmodium falciparum parasite created by triple gene deletion

Molecular Therapy

Volumn 22, Issue 9, 2014, Pages 1707-1715

  Mikolajczak, Sebastian A ^a   Lakshmanan, Viswanathan ^a   Fishbaugher, Matthew ^a   Camargo, Nelly ^a   Harupa, Anke ^a   Kaushansky, Alexis ^a   Douglass, Alyse N ^a   Baldwin, Michael ^a   Healer, Julie ^b   O'neill, Matthew ^b   Phuong, Thuan ^b   Cowman, Alan ^b   Kappe, Stefan H I ^a,c  

^a SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

^b WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIVE VACCINE; MALARIA VACCINE; PLASMODIUM FALCIPARUM VACCINE; PROTEIN P52; UNCLASSIFIED DRUG; PROTOZOAL PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENE; GENE DELETION; GENE TARGETING; GENETIC ENGINEERING; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEXT GENERATION SEQUENCING; NONHUMAN; P36 GENE; P52 GENE; PLASMODIUM YOELII INFECTION; PREVALENCE; SAP1 GENE; ANIMAL; ANOPHELES; BLOOD; DISEASE MODEL; GENE INACTIVATION; GENETICS; MALARIA FALCIPARUM; PARASITOLOGY; PHYSIOLOGY; PLASMODIUM FALCIPARUM;

ANIMALS; ANOPHELES; DISEASE MODELS, ANIMAL; GENE DELETION; GENE KNOCKOUT TECHNIQUES; HUMANS; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; VACCINES, ATTENUATED;

EID: 84964312800     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2014.85     Document Type: Article

References (41)

1. World Health Organization. Malaria Control Department. (2013). Malaria report 2013. http://www.who.int/malaria/publications/world-malaria-report-2013/en.
2. Greenwood, BM, Fidock, DA, Kyle, DE, Kappe, SH, Alonso, PL, Collins, FH et al. (2008). Malaria: Progress, perils, and prospects for eradication. J Clin Invest 118: 1266-1276.
3. Nussenzweig, RS, Vanderberg, J, Most, H and Orton, C (1967). Protective immunity produced by the injection of x-irradiated sporozoites of plasmodium berghei. Nature 216: 160-162.
4. Clyde, DF, Most, H, McCarthy, VC and Vanderberg, JP (1973). Immunization of man against sporozite-induced falciparum malaria. Am J Med Sci 266: 169-177.
5. Clyde, DF, McCarthy, VC, Miller, RM and Hornick, RB (1973). Specificity of protection of man immunized against sporozoite-induced falciparum malaria. Am J Med Sci 266: 398-403.
6. Clyde, DF (1975). Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites. Am J Trop Med Hyg 24: 397-401.
7. Rieckmann, KH, Carson, PE, Beaudoin, RL, Cassells, JS and Sell, KW (1974). Letter: Sporozoite induced immunity in man against an Ethiopian strain of Plasmodium falciparum. Trans R Soc Trop Med Hyg 68: 258-259.
8. Rieckmann, KH, Beaudoin, RL, Cassells, JS and Sell, KW (1979). Use of attenuated sporozoites in the immunization of human volunteers against falciparum malaria. Bull World Health Organ 57 (suppl. 1): 261-265.
9. Rieckmann, KH (1990). Human immunization with attenuated sporozoites. Bull World Health Organ 68: 13-16.
10. Roestenberg, M, McCall, M, Hopman, J, Wiersma, J, Luty, AJ, van Gemert, GJ et al. (2009). Protection against a malaria challenge by sporozoite inoculation. N Engl J Med 361: 468-477.
11. Seder, RA, Chang, LJ, Enama, ME, Zephir, KL, Sarwar, UN, Gordon, IJ et al.; VRC 312 Study Team. (2013). Protection against malaria by intravenous imm unization with a nonreplicating sporozoite vaccine. Science 341: 1359-1365.
12. Hoffman, SL, Goh, LM, Luke, TC, Schneider, I, Le, TP, Doolan, DL et al. (2002). Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis 185: 1155-1164.
13. Mueller, AK, Camargo, N, Kaiser, K, Andorfer, C, Frevert, U, Matuschewski, K et al. (2005). Plasmodium liver stage developmental arrest by depletion of a protein at the parasite-host interface. Proc Natl Acad Sci USA 102: 3022-3027.
14. Mueller, AK, Labaied, M, Kappe, SH and Matuschewski, K (2005). Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature 433: 164-167.
15. Tarun, AS, Dumpit, RF, Camargo, N, Labaied, M, Liu, P, Takagi, A, et al. (2007). Protracted sterile protection with Plasmodium yoelii pre-erythrocytic genetically attenuated parasite malaria vaccines is independent of significant liver-stage persistence and is mediated by CD8+ T cells. J Infect Dis 196: 608-616.
16. van Schaijk, BC, Janse, CJ, van Gemert, GJ, van Dijk, MR, Gego, A, Franetich, JF et al. (2008). Gene disruption of Plasmodium falciparum p52 results in attenuation of malaria liver stage development in cultured primary human hepatocytes. PLoS One 3: e3549.
17. Ishino, T, Chinzei, Y and Yuda, M (2005). Two proteins with 6-cys motifs are required for malarial parasites to commit to infection of the hepatocyte. Mol Microbiol 58: 1264-1275.
18. Douradinha, B, van Dijk, M, van Gemert, GJ, Khan, SM, Janse, CJ, Waters, AP et al. (2011). Immunization with genetically attenuated P52-deficient Plasmodium berghei sporozoites induces a long-lasting effector memory CD8+ T cell response in the liver. J Immune Based Ther Vaccines 9: 6.
19. Labaied, M, Harupa, A, Dumpit, RF, Coppens, I, Mikolajczak, SA and Kappe, SH (2007). Plasmodium yoelii sporozoites with simultaneous deletion of P52 and P36 are completely attenuated and confer sterile immunity against infection. Infect Immun 75: 3758-3768.
20. VanBuskirk, KM, O'Neill, MT, De La Vega, P, Maier, AG, Krzych, U, Williams, J et al. (2009). Preerythrocytic, live-attenuated Plasmodium falciparum vaccine candidates by design. Proc Natl Acad Sci USA 106: 13004-13009.
21. Spring, M, Murphy, J, Nielsen, R, Dowler, M, Bennett, JW, Zarling, S et al. (2013). First-in-human evaluation of genetically attenuated Plasmodium falciparum sporozoites administered by bite of Anopheles mosquitoes to adult volunteers. Vaccine 31: 4975-4983.
22. Aly, AS, Mikolajczak, SA, Rivera, HS, Camargo, N, Jacobs-Lorena, V, Labaied, M et al. (2008). Targeted deletion of SAP1 abolishes the expression of infectivity factors necessary for successful malaria parasite liver infection. Mol Microbiol 69: 152-163.
23. Aly, AS, Lindner, SE, MacKellar, DC, Peng, X and Kappe, SH (2011). SAP1 is a critical post-transcriptional regulator of infectivity in malaria parasite sporozoite stages. Mol Microbiol 79: 929-939.
24. Silvie, O, Goetz, K and Matuschewski, K (2008). A sporozoite asparagine-rich protein controls initiation of Plasmodium liver stage development. PLoS Pathog 4: e1000086.
25. Annoura, T, Ploemen, IH, van Schaijk, BC, Sajid, M, Vos, MW, van Gemert, GJ et al. (2012). Assessing the adequacy of attenuation of genetically modified malaria parasite vaccine candidates. Vaccine 30: 2662-2670.
26. O'Neill, MT, Phuong, T, Healer, J, Richard, D and Cowman, AF (2011). Gene deletion from Plasmodium falciparum using FLP and Cre recombinases: implications for applied site-specific recombination. Int J Parasitol 41: 117-123.
27. Vaughan, AM, Mikolajczak, SA, Wilson, EM, Grompe, M, Kaushansky, A, Camargo, N et al. (2012). Complete Plasmodium falciparum liver-stage development in liverchimeric mice. J Clin Invest 122: 3618-3628.
28. Duffy, PE, Sahu, T, Akue, A, Milman, N and Anderson, C (2012). Pre-erythrocytic malaria vaccines: identifying the targets. Expert Rev Vaccines 11: 1261-1280.
29. Sheehy, SH, Douglas, AD and Draper, SJ (2013). Challenges of assessing the clinical efficacy of asexual blood-stage Plasmodium falciparum malaria vaccines. Hum Vaccin Immunother 9: 1831-1840.
30. Agnandji, ST, Lell, B, Fernandes, JF, Abossolo, BP, Methogo, BG, Kabwende, AL et al.; RTS, S Clinical Trials Partnership. (2012). A phase 3 trial of RTS, S/AS01 malaria vaccine in African infants. N Engl J Med 367: 2284-2295.
31. Khan, SM, Janse, CJ, Kappe, SH and Mikolajczak, SA (2012). Genetic engineering of attenuated malaria parasites for vaccination. Curr Opin Biotechnol 23: 908-916.
32. Ploemen, IH, Croes, HJ, van Gemert, GJ, Wijers-Rouw, M, Hermsen, CC and Sauerwein, RW (2012). Plasmodium berghei ?p52&p36 parasites develop independent of a parasitophorous vacuole membrane in Huh-7 liver cells. Plos One 7: e50772.
33. Finney, OC, Keitany, GJ, Smithers, H, Kaushansky, A, Kappe, S and Wang, R (2014). Immunization with genetically attenuated P. falciparum parasites induces long-lived antibodies that efficiently block hepatocyte invasion by sporozoites. Vaccine 32: 2135-2138.
34. Vaughan, AM, O'Neill, MT, Tarun, AS, Camargo, N, Phuong, TM, Aly, AS et al. (2009). Type II fatty acid synthesis is essential only for malaria parasite late liver stage development. Cell Microbiol 11: 506-520.
35. Butler, NS, Schmidt, NW, Vaughan, AM, Aly, AS, Kappe, SH and Harty, JT (2011). Superior antimalarial immunity after vaccination with late liver stage-arresting genetically attenuated parasites. Cell Host Microbe 9: 451-462.
36. van Schaijk, BC, Kumar, TR, Vos, MW, Richman, A, van Gemert, GJ, Li, T et al. (2014). Type II Fatty Acid Biosynthesis Is Essential for Plasmodium falciparum Sporozoite Development in the Midgut of Anopheles Mosquitoes. Eukaryot Cell 13: 550-559.
37. Maier, AG, Braks, JA, Waters, AP and Cowman, AF (2006). Negative selection using yeast cytosine deaminase/uracil phosphoribosyl transferase in Plasmodium falciparum for targeted gene deletion by double crossover recombination. Mol Biochem Parasitol 150: 118-121.
38. Lambros, C and Vanderberg, JP (1979). Synchronization of Plasmodium falciparum erythrocytic stages in culture. J Parasitol 65: 418-420.
39. Wu, Y, Sifri, CD, Lei, HH, Su, XZ and Wellems, TE (1995). Transfection of Plasmodium falciparum within human red blood cells. Proc Natl Acad Sci USA 92: 973-977.
40. Kaushansky, A, Rezakhani, N, Mann, H and Kappe, SH (2012). Development of a quantitative flow cytometry-based assay to assess infection by Plasmodium falciparum sporozoites. Mol Biochem Parasitol 183: 100-103.
41. Vaughan, AM, Mikolajczak, SA, Camargo, N, Lakshmanan, V, Kennedy, M, Lindner, SE et al. (2012). A transgenic Plasmodium falciparum NF54 strain that expresses GFP-luciferase throughout the parasite life cycle. Mol Biochem Parasitol 186: 143-147.